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Abstract:  
Introduction: Long term outcome studies in Takayasu arteritis (TA) are few and limited by 
small sample size. In this study, we analysed the outcome of treatment in a large series of TA 
patients with a minimum follow up period of ≥ 12 months by objective instruments.  
Materials and Methods: Patients with TA satisfying the 1990 ACR, Ishikawa’s, Sharma’s or 
EULAR/PRESS criteria were recruited from our clinics between 1998 and 2016. Only 
patients with a minimum follow up of 12 months were studied. Data related to clinical 
presentation, disease extent [DEI.Tak score], activity [Indian Takayasu arteritis clinical 
activity score i.e. ITAS-A (CRP)] and damage score [Takayasu Arteritis Damage Score i.e. 
(TADS)], angiography and treatment were collected for all patients. Response to treatment 
was categorised as complete response (CR), partial response (PR) or refractory disease. 
Patients with sustained CR on prednisolone dose of ≤ 5mg/day were classified as having 
sustained inactive disease. Appropriate statistical tests were used for parametric and non-
parametric data. Relapse free survival was projected by Kaplan Meir curve. Cox proportional 
hazards regression plot was used to compare the efficacy of medications. Predictors of 
sustained response were identified by logistic regression and a prediction model was 
constructed.  
Results: Among 503 TA patients examined during study period, 251 had follow-up of ≥ 12 
months and were included in this study. Median follow up duration was 42 months (IQR: 24-
81, maximum 240 months). Patients (81.7% females, mean age of  29.2 ± 11.8 years, 
symptom duration of 24 (6-70) months) were treated by a uniform protocol that included high 
dose steroids (n=239) plus concurrent steroid-sparing immunosuppressant (n=235) with 
mycophenolate in majority. Biological agents (n= 44 patients) and revascularisation 
procedures were used in symptomatic patients after control of disease activity. At 1
st
 follow 
up, CR (ITAS2010 =0, CRP <6mg/L and non-progressive disease on angiography) was 
observed in 173 (68.9%), partial response (PR) in 42 (16.7%) and no response was seen in 
only 36 (14%) patients. CR was sustained till the last follow up in 116 (65.9%) of 173 
patients with initial CR, while 87 (49.4%) of them achieved sustained inactive disease. 
Disease activity relapsed at a median duration of 37 (29.9- 44.1) months in 56 patients. 
Cumulative relapse free survival was 93%, 73%, 66% and 52% at 1, 3, 5 and 10 years 
 respectively. Baseline CRP <6.2, DEI.Tak <9 and angiographic type 4 disease predicted 
sustained inactive disease and a model comprising these parameters showed sensitivity and 
specificity of 70% and 61.1%. Two fatalities were observed. New vascular lesions during 
follow up were observed in 50 (19.9%) patients. Overall, 92.8% had at least one period of CR 
or PR while 7.2% were refractory to treatment till the last follow up. Damage progression 
(∆TADS >1) was arrested in 68% of patients and was lower in patients with sustained 
inactive disease [0 (0-1)] as compared to the rest [1 (0-2.75)], p=0.000. Both early response 
as well as cumulative hazard for relapse was similar between patients initiated on 0.5mg/kg/d 
and 1mg/kg/d steroids.  
Conclusions: Our strategy of upfront combination immunosuppressant therapy stabilised 
disease activity in 92.8% of patients while 7.2% had true refractory disease. Relapse free 
survival was 66% at 5 years and 52% at 10 years. Damage progression was arrested in 68% 
and only 2 fatalities were observed. Initial steroid dose of 0.5mg/kg/day had similar efficacy 
as 1mg/kg/day dose.   
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TA – Takayasu arteritis, ITAS 2010- Indian Takayasu activity score 2010, EMR- Electronic 
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Damage Score, DEI.Tak- Disease Extent Index- Takayasu arteritis, CR- Complete response 
PR- Partial response, TCZ- Tocilizumab, MMF- mycophenolate, AZA- Azathioprine, MTX- 
Methotrexate, AUC- Area under curve, OR- Odds Ratio, CCF- Cleveland clinic foundation,   
  
  
 
 
Introduction:  
Takayasu arteritis (TA) is a prototypic large vessel vasculitis characterised by granulomatous 
inflammation of the aorta, its main branches and pulmonary arteries. Untreated inflammation 
often leads to stenosis and / or occlusion of involved arteries; less frequently, dilatation or 
aneurysm formations are the sequelae [1,2]. The disease is rare but somewhat more common 
in Asians. Over the past 16 years, we have created a database of 503 patients with TA in our 
tertiary care, teaching hospital. Several clinical series from various parts of the world have 
highlighted different clinical aspects of this disease; most of these studies are retrospective in 
nature except one from the NIH and a small Indian series [3,4]. Arnaud et al, in their 
multicentre retrospective study from France have looked at the influence of ethnic 
background on clinical phenotypes of TA, while Yang et al addressed the predictors of 
survival in Chinese patients. On the other hand, the two recent Japanese studies analysed 
changes in the profile of TA in the current decade as compared to those diagnosed in the past, 
as well as the effects of gender and age on clinical manifestations [5–8]. Even though many 
case series from various centres across the world have been published, data on long term 
outcome is negligible and only small series of patients exist with ≥ 1year follow up. Schmidt 
et al from Mayo clinic described 126 patients with TA, but the outcome data was available 
only for 79 of them [9]. There is no long term study even from South Asia including India, 
one of the largest reservoirs of TA. We report here the outcome data of 251 patients from our 
single centre cohort of TA, restricted to patients with follow up duration of at least 12 
months.  
In this study, we analysed both retrospectively and prospectively, the outcome of treatment in 
TA by objective instruments.  
 
Materials and Methods: 
2.1 Data extraction: The data for this study has been collected in retrospective manner from 
our institute’s electronic medical records (EMR) for 179 patients and prospectively for the 
rest of the cohort (n=72). EMR include the records of all discharge summaries, outpatient 
 medical reports and investigation reports in an electronic workstation by our institute and  it 
is in existence since the year 2002. In addition, doctors’ notes and inpatient case records are 
also saved as hard copies. Scanned documents are also preserved as soft copies for all 
patients attending this hospital since 2012; these can be retrieved and made available for 
clinical research after approval from the institute research and ethics committee, Thus, the 
data in these records has been prospectively entered and saved, but have been extracted for 
this study in a retrospective manner.  
2.2 Patients: 
A total of 503 patients with TA, attending our outpatient and in-patient services during the 
period from January, 1998 to April, 2016 and satisfying the 1990 ACR criteria, Ishikawa 
criteria or Sharma’s modification of Ishikawa criteria or EULAR/PRESS criteria for 
childhood TA were studied [10–12]. Of these, 251 consecutive patients had complete records 
of clinical details with a follow up duration of at least 12 months and therefore, were eligible 
to be included in this study. Details of demography, clinical as well as angiographic features, 
extent of clinical disease assessed by DEI.Tak, cumulative damage assessed by TADS 
(Takayasu arteritis damage score), disease activity assessed by ITAS2010 (Indian Takayasu 
activity score, 2010) along with laboratory parameters i.e. C-Reactive Protein (CRP) and 
Erythrocyte sedimentation rate (ESR) were noted for each visit till the last recorded follow 
up.  
2.3 Disease assessment: 
The disease was categorised into 5 subtypes according to Hata’s classification criteria based 
on angiographic findings [13]. The baseline extent of disease was assessed by DEI.Tak score 
[14,15].  
During the follow up visits, we defined disease activity by a hybrid composite score namely, 
ITAS-A(CRP) which incorporates both clinical assessment by ITAS-2010 and CRP as 
biomarker [16].  
Study definitions:  
Juvenile onset TA was defined as TA patients with onset of 1
st
 symptom at or prior to the age 
of 16 years, while those with age of onset beyond 16 years of age were labelled as adult onset 
TA.  
 Disease activity at each visit was defined as  
1. Clinical activity: by presence of any one of the following:  
1a. ITAS 2010 ≥ 2 (not attributable by in-stent restenosis)  
1b. ITAS-A (CRP) ≥ 3, at least one point should be contributed by clinical criteria as 
in ITAS proforma (16) 
2. Imaging activity: if there was presence of de-novo lesion on follow up angiography or 
stenosis of the same vessel extending beyond stent margins 
3. Biomarker activity: defined by persistently raised CRP as well as ESR on 2 consecutive 
visits without any alternative explanation like infection. 
Response to Treatment was classified as  
A. Complete response (CR): absence of all of these criteria of disease activity as mentioned 
above  
When the patient maintained complete response throughout the follow up period, the 
outcome was called persistent complete response. 
The subset of patients with persistent CR during the entire follow up period, who were able to 
reduce daily steroid dose to ≤ 5mg, were classified as having sustained inactive disease. 
B. Partial response (PR) was defined as ITAS-A (CRP) value of 1 or 2 along with any 
improvement in disease activity by any of the 3 categories of criteria as above, not amounting 
to complete normalisation. This included downward trend from baseline activity by clinical, 
imaging or laboratory criteria. 
 If a patient attained CR or PR anytime during study period, whether early or late, they were 
considered as treatment responders.  
C. Relapsing-remitting disease: Patients who had return of disease activity as defined above 
after having attained complete response.  
D. Refractory disease: Inability to achieve CR or PR during the entire follow up period in 
spite of treatment escalation as per our protocol. 
 2.4 Medical Therapy protocol: The patients in our study were treated by medical therapy 
according to protocol adopted by our unit based on clinical, real life efficacy and socio-
economic background relevant to our resource limited set up.  The treatment protocol is 
depicted in figure-1.  Patients with active disease were initiated on high dose steroids 
(1mg/kg/day of prednisolone or equivalent dose of deflazacort during the period prior to 2009 
and  0.5mg/kg/day of the same after 2009) with or without biological agents [mostly 
interleukin-6 receptor blocker tocilizumab (TCZ) or anti-tumor necrosis alpha agents]. 
Concurrently, one steroid sparing immunosuppressive agent [mycophenolate (MMF), 
azathioprine (AZA) or methotrexate (MTX)] were routinely initiated upfront at the 1
st
 visit. 
Based on our earlier experience (17), MMF has been the first choice steroid sparing 
immunosuppressant in our clinic. Those who could not afford MMF, azathioprine was the 
next option. Methotrexate was given only to extremely non-affording patients or in 
exceptional cases with quiescent disease without any major target organ damage. The dose of 
MMF was maintained between 2-3 gm/day (majority 2 gm/day) and the dose adjustments 
were done after assaying the MMF levels by 6 hour AUC. The dosage of AZA and MTX 
were as mentioned in figure-1. After steroids are slowly tapered down to ≤5mg/day of 
prednisolone or ≤6mg/day of deflazacort while the treatment response was maintained 
(ITAS-A =0), further attempt to lower the dose of steroid sparing immunosuppresants were 
made very cautiously.  
In addition, symptomatic vascular stenosis with >70% occlusion were subjected to 
revascularisation procedures, after initial control of disease activity by medical treatment, 
usually at 1
st
 or 2
nd
  three monthly follow up visit. Endovascular percutaneous trans-luminal 
angioplasty with or without placement of stent were preferred choices over surgery in our 
centre. Open surgeries mainly renal auto-transplantation or aneurysmal repair, were opted in 
small number of cases with lesions not amenable to endovascular intervention.  
 
 
 
 
 
 Figure 1: Treatment protocol for TA patients in the present study
#
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The preferred immunosuppressant is mycophenolate (MMF) (2-3 gm/day). For patients with limited finances, azathioprine (AZA) 
(2mg/kg/day) is used; while methotrexate (MTX) use 15-25mg/week) is restricted only to those patients with mild, non-organ threatening 
disease and severe financial constraints.  
$Steroids were oral prednisolone or equivalent dose of deflazacort    
 # For critical symptomatic vascular narrowing requiring revascularisation after medical control of disease activity / clinically (ITAS-A) or 
angiographically aggressive disease / young patients requiring rapid taper of steroids / myocardial involvement  
Continue steroids$ on ongoing dose  
+ steroid sparing 
immunosuppressant*   
 
Steroid$ (0.5-1 mg/k/day) + 
Steroid sparing immunosuppressant* + 
Tocilizumab (3 -6 doses, 8mg/kg/ month) 
/ high dose pulse steroids in specific situations# 
Treatment response is assessed at every 3-6 months by ITAS-A (CRP) and at every 1-2 year by 
conventional/MR/CT angiography or PET-CT 
 
Baseline visit 
Disease activity assessment by ITAS-A (CRP)   
Stable disease on prior immunosuppression 
Angiography (Conventional/MRA/CTA/ PETCT) 
– no progression  
Active disease (as per definitions in the text) 
Active disease  
TCZ (3-6 cycles) / pulse steroids + 
MMF dose escalation if MMF levels are low + 
Steroid$ dose at 0.5mg/kg/day  
Stable disease-  
taper steroids$ by (10% every 3 weeks to 
7.5mg/d then 10% every 2 months to 5mg/d) 
Continue MMF/AZA/MTX  
Active disease: TNFi or  
steroid$ escalation to 1mg/kg/day 
+pulse CYC  
Slow cautious taper of 
MMF/AZA/MTX 
Stable disease  
Relapse  
Stable disease  If Active – considered as refractory disease   
Follow up with anti-platelet +/- statins/ 
consider intervention/ ?experimental 
therapy    
2 years in CR  
 Note: All patients are initiated on anti-platelet therapy and additional treatment with statins and anti-hypertensive drugs is given as and when 
required. Re-vascularisation procedures are performed after controlling disease activity when needed.  
 
2.5 Statistical analysis: Demographic variables are depicted as mean ± S.D. or median 
(interquartile range or IQR) wherever applicable. Intergroup comparisons were performed 
using nonparametric test (Mann Witney U test) for continuous variables or χ2 test for 
categorical variables. Pearson coefficient was used to determine correlation between two 
continuous parameters. Logistic regression was performed to ascertain the independent effect 
of various parameters on different aspects of disease.  
Predictors of sustained inactive disease were identified using regression analysis. A 
prediction model has also been constructed incorporating the parameters which were 
significant to the precision levels of 10% in regression analysis. Area under curve (AUC) for 
individual predictors as well as the prediction model were generated by constructing receiver 
operating curves (ROC) and optimal cut off values were determined.  The overall survival 
and relapse free survival were projected by Kaplan Meir survival curve.   
Wherever applicable, Cox proportional hazards regression plot was used to compare the 
efficacy of medications on disease course. SPSS version 16 was used for all analysis.  
 
Results:  
3.1 Baseline demography and disease extent: In total, 251 patients with follow up details of 
≥ 1 year were included in this study. Majority (n=205, 81.7%) were females with mean age at 
1
st
 visit to our clinics of 29.2 ± 11.8 years and mean age at onset of symptoms of 24 ± 11.0 
years. Median duration of disease prior to presentation to us was 24 (6-70) months. At 
baseline, the most common clinical presentations included pulse loss, claudication, and 
hypertension which were noted in 60.6%, 59% and 53.4%  of patients respectively 
(supplementary figure-S1). Detailed angiography was done for all but 3 patients; 9 of them 
had undergone only CT/MR angiogram, while the remaining vast majority had undergone 
conventional angiography (supplementary figure-S2). Type V disease was the commonest 
type (n=135, 54.2%) followed by type 4 and type 1 (n=45, 18% each). The commonest 
comorbidity was tuberculosis in 26 patients; diabetes mellitus was present in 6 patients.  
 Median DEI.Tak was 9 (IQR: 6-13). Median ITAS 2010 score at baseline was 8 (2-12) and 
ITAS-A scored in 229 patients was 8 (3-14). Raised CRP (≥6mg/L) and ESR (≥ 20 mm/1st 
hr) at baseline was observed in 135 (58.9%) and 183 (78.2%) patients respectively. Baseline 
TADS, scored in 248 patients, was 6 (4-10). A modest correlation was observed between the 
diagnostic delay and TADS score with Pearson correlation coefficient of 0.698 (p=0.027). 
Altogether, 81 patients (32.3%) had present or prior history of major complications at the 
time of presentation to our unit; of these, hypertensive emergency including accelerated 
hypertension, cerebrovascular accident and aortic regurgitation were the most common ones.  
  
  
3.2 Treatment details: Medical immunosuppressive therapy was initiated for the large 
majority of patients. Steroids (deflazacort in majority) were started in 239 (95.2%) patients. 
The initial steroid dose was 1 mg/kg/day for 93 (37%) patients, 0.75 mg/kg/day for 4 patients 
(1.6%), 0.5mg/kg day for 113 patients (45%), while 29 (11.6%) patients received 
<0.5mg/kg/day steroids. Steroid sparing immunosuppressive agents were initiated in 235 
(93.6%) patients upfront along with steroids from day 1. Mycophenolate was the most 
frequently used immunosuppressant (160, 63.7% patients) followed by azathioprine (54, 
21.5%) and methotrexate (20, 8.0%). Tocilizumab with or without mycophenolate was used 
in 14 patients (5.6%).  
Thirteen patients (5.2%) were not initiated on any steroid and/or steroid sparing 
immunosuppressant due to various reasons, such as inactive and non-progressive disease 
prior to 1
st
 consultation with our unit, pregnancy, tuberculosis and other contraindications.   
Revascularisation procedures were performed in 180 (71.7%) patients between 3 and 6 
months after initiation of medical therapy, provided the disease activity was under control. 
The majority (n=174; 96.7%) were endovascular interventions, while 14 patients (3.3%) 
underwent open surgeries as mentioned in methods above.  
3.3 Disease outcome during follow up (figure 2, 3A and 3B): Median follow up duration 
was 42 months (IQR: 24-81, maximum 240 months) with 192 of the total cohort of patients 
(76%) following up for ≥24 months, while 88 (35%) were followed up for ≥ 5 years. Good 
compliance to treatment was observed in 80.5% of patients; although 16% defaulted for a 
short period in between, only 13.1% of patients were non-compliant to medical treatment 
throughout the follow up period.  
Short term outcome (response at 1st follow up visit): Overall, 215 patients (85.6%) responded 
to treatment at 1
st
 follow up visit; 173 of them (68.9%) achieved complete response (ITAS 
2010 =0, CRP <6mg/L and non-progressive disease on angiography), while 42 (16.7%) 
patients had partial response. Only 36 patients (14%) did not show any initial response to 
treatment (Figure-2). Since majority (95%) of patients were on steroids plus second line 
immunosuppressant combination, we did not compare their outcome with that of a negligible 
number of patients (n=4) on steroids alone.  
 
  
Figure-2: Outcome of 251 TA patients with a follow up of ≥ 12 months in this series  
 
 
*includes 1 fatality each 
Long term outcome (median follow up 42 months): During further follow up at 42 (IQR: 24-
81) months, 116 patients (65.9%) amongst the 173 initial complete responders maintained 
their CR status till their last follow up visit. Steroid dose could be tapered to ≤ 5mg/day of 
prednisolone or ≤ 6mg/day of deflazacort by last follow up visit in 87 (49.4%) patients, who 
also maintained the initial complete response. They were, therefore, classified as having 
sustained inactive disease. However, only 13 (14.9%) of the 87, could be completely taken 
off 2
nd
 line immunosuppressive agents at the last visit (15 continued on azathioprine, 56 on 
mycophenolate and 3 on methotrexate). Discontinuation of both steroids and 
immunosuppressive agents could only be achieved in 11 patients.   
 Relapse of disease activity, after an initial complete response, was observed in 56 patients 
(32.4% of 173 patients with initial CR i.e. 22.3% of total cohort of 251 patients) with median 
time to relapse of 37 (29.9- 44.1) months. Later during further follow up till the last visit, 
treatment escalations led to a complete or partial response in 32 and 7 of these 56 relapsed 
patients, respectively. Only 17 of them (30.4% of 56 relapsed patients i.e. 6.8% of total 
cohort) did not regain CR or PR till the last follow up visit.  
Only two fatalities were observed in the whole cohort during the study period; one patient 
expired due to sepsis following a osteoporotic vertebral fracture and another patient with 
underlying dilated cardiomyopathy had succumbed to acute pulmonary edema.  
One patient had developed acute myeloid leukemia (at 50 years of age) during 48th month of 
follow up and was excluded from analysis, though the patient was alive till the last follow up 
visit.  
Among the initial non-responders, 19 patients eventually responded (CR in 16, PR=in 3) after 
escalating steroid dose with or without addition of biological agent TCZ (n=9). Thus, of the 
entire cohort, only 15 patients (6%) did not attain complete or partial response anytime 
during follow up, in-spite of treatment escalation.  
The Kaplan Meir curve showed cumulative relapse free survival to be 93%, 73%, 66% and 
52% at 1 year, 3 years 5 years and 10 years respectively (figure-3A). During any follow up 
interval period, initial high overall response rate (CR+PR) was noted to persist consistently 
(figure 3B). Even the lowest overall response rate was 68.2% during 8-24 months follow up 
period; beyond 2 years this figure peaked to ≈ 80% till the last follow up.  
Figure 3A: Cumulative relapse free survival in patients with TA  
Follow up is censored at 150 months as very few of our patients followed up beyond this time 
point and the last relapse was observed at 144 months.  
 
   
  
Figure 3B: Disease activity status at various time intervals of follow up (months)  
 
 
Angiographic progression: Among the patients with active disease at any one time point 
during follow up, repeat angiography showed new vascular lesions in 50 (19.9%) patients, 11 
of whom had isolated angiographic progression without clinical and laboratory criteria. 
Others had isolated biomarker activity (n= 32), clinical and biomarker activity (n= 19), only 
clinical activity (n= 12), while the disease was active by all three criteria in 19 patients.    
Disease outcome and damage at last visit: On cross sectional analysis at their last recorded 
visit, 176 patients (70.5%) had stable disease (i.e. complete response) with 127 (72.2%) of 
them maintaining stable disease status on ≤ 5mg/day of prednisolone or ≤ 6mg/day of 
deflazacort. Partial response was observed in 37 (14.7%) patients, while 35 patients (14.3%) 
had active disease state.  Activity of TA could not be clearly ascertained in 3 patients due to 
malignancy in 1 and active TB infection in 2 patients. These 3 patients are not included in 
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 final analysis of outcome. Overall, median ITAS-A CRP score at the last follow up visit 
(calculated in 248 patients) was 0 (IQR: 0-2).  
Median dose of steroids at last visit was 5 (2.5-10; range 0-70) mg/day of prednisolone or 
equivalent dose of deflazacort. Steroids had been discontinued in 37 patients (14.7%) and 
tapered to≤ 7.5mg of prednisolone or equivalent dose of deflazacort in 175 patients (70%) by 
the last visit. Majority of patients (n=226, 90%) were on steroid sparing immunosuppressive 
agents at the last visit.  
Damage progression: Median TADS at last follow up visit was 8 (4.25-11, range: 0-24). 
Increment in TADS from 1
st
 visit to the last visit (∆ TADS calculated for 244 of these 
patients) was 1.0 (IQR: 0-2, range 0-10). Majority (68%) had no or minimal progression of 
damage (delta TADS score of 0 and 1 in 103 and 63 patients respectively). Median delta 
TADS was significantly lower in patients with sustained inactive disease [0 (0-1)] as 
compared to rest of the cohort [1 (0-2.75)], p=0.000.The increment in TADS score in patients 
with different disease courses is shown in table-1. 
Table-1: Increment in TADS score (∆TADS) in patients with different disease courses   
Parameter Persistently 
stable (any 
steroid dose)  
Partial 
response 
Relapsing/ 
Remitting 
Delayed 
response 
Persistently 
active  
p1* p2* p3* 
No. of patients 
with ∆TADS 
calculated  
112  41 54 7 28  
 
 
0.000 
 
 
 
0.000 
 
 
 
0.85 Median ∆TADS 0 (0-1,  
range 0-9) 
1 (0-2,  
range: 0-
8) 
1 (0-3,  
range 0-9) 
2 (0=3, 
range 0-
3) 
2 (0.25-3,  
range 0-10) 
p1 - persistently stable vs persistently active group  
p2 – persistently stable vs relapsing disease 
p3 – relapsing vs persistently active disease  
 
3.4 Predictors of outcome: Our second objective was to construct a prediction model for the 
subset of 87 patients with less aggressive disease i.e. those with sustained inactive disease 
(persistent complete response with prednisolone dose of ≤ 5mg/day or equivalent at last 
visit). Univariate analysis for clinical associates of sustained inactive disease showed 
significantly lower baseline ESR, CRP, and DEI.Tak values in these patients as compared to 
other patients (p= 0.000). Angiographic type 4 disease was the most frequent subset in 
patients with sustained inactive disease as compared to rest of the patients (p=0.002). The 
scenario was diametrically opposite for type 5 disease (p= 0.019) (supplementary table S3). 
 The optimal cut-off values which differentiated patients with sustained inactive disease from 
rest of the cohort included baseline CRP < 6.2 mg/L, ESR <32 mm/1
st
 hr, DEI.Tak < 9 with 
an ROC curve AUC of 66.2%, 63.1% and 60.7% respectively.  Baseline ITAS-2010 did not 
significantly predict sustained inactive disease.  
Multivariate analysis showed baseline CRP < 6.2 mg/L and type 4 disease to be independent 
predictors of sustained inactive disease with an adjusted OR of 2.65 (1.38- 5.08, p= 0.003) 
and  2.213 (1.003- 4.884, =0.049) respectively. Initial steroid dose and ESR values did not 
predict this subset. DEI.Tak scores of <9 was also not significantly associated with subset of 
responders, but it had a trend towards independent association, with an OR of 1.74 (0.948- 
3.2, p= 0.074) and therefore, it was included for construction of the prediction model below.  
We constructed a model assigning the OR values of CRP, angiographic  type 4 disease and 
DEI.Tak to those patients with values above respective cut-offs determined by ROC as 
mentioned above (table-2). At a composite score value of 1.98, the prediction model 
differentiated the subset with sustained inactive disease from other patients, with an AUC of 
70.2 (63.3-77.2, p= 0.000) and sensitivity and specificity of 70% and 61.1%.  
Table-2: Prediction model for sustained inactive disease in TA patients  
Item  Value  Score assigned  
CRP (mg/L) <6.2 2.65 
Type 4 disease  Present  2.21 
DEI.Tak <9 1.74 
A total score of >1.98 predicted sustained inactive disease  
 
Analysis of predictors of refractory disease revealed  that patients with refractory disease had 
higher age at onset [31 (25-36) vs 24 (16-30), p=0.019], lesser diagnostic delay [3 (4-11) 
months vs 9 (2-24) months, p=0.027], higher DEI.Tak score [11 (8-15) vs 9 (6-12)], p=0.074 
and higher ITAS 2010 score [11 (8-15) vs 8 (1-12), p= 0.026]. Abdominal aorta involvement 
was less common in patients with refractory disease (2/15 vs 112/235, p=0.01). Multivariate 
analysis showed abdominal aortic involvement to be a significant negative predictor of 
refractory disease [OR 0.067 (0.006- 0.79), p= 0.01], thus, indirectly reaffirming the results 
of analysis reflecting predictors of sustained inactive disease.  
 
  
3.5 Comparison of efficacy of various immunosuppressive agents:   
Initial response (Induction regime): As far as steroid dose is concerned, there were 2 subsets 
namely those initiated on 1mg/kg/d (n=93) and those on 0.5mg/kg/d (n=113) of prednisolone 
or equivalent dose of deflazacort (in major proportion). The smaller group of patients on 0.75 
mg/kg/day and those on <0.5mg/kg/day comprised a heterogeneous category and hence were 
not  analysed in the comparison. A comparison between those initiated on 0.5mg/kg/d and 
1mg/kg/d steroid showed that early complete response was not significantly different 
between the two groups (74.3% vs 62.4% respectively), p=0.065. Cumulative hazard for 
relapse in patients with initial complete response was not different either between the two 
steroid regimens [HR=0.889 (95%CI 0.481-1.641), p=0.71] after adjusting for baseline CRP, 
ESR, juvenile onset type, type 4 disease, compliance to treatment and use of tocilizumab 
(Figure 4).  
Figure 4: Comparison of cumulative hazards for relapse between patients on 
1mg/kg/day and 0.5mg/kg/day of steroids 
Vertical lines denote median time to relapse in two groups (18 months in patients on initial 
steroid dose of 1mg/kg/d and 21.5 months in patients on initial steroid dose of 0.5mg/kg/day) 
  
Seventy patients switched amongst the steroid sparing immunosuppressive agents during 
follow up. Response was achieved in 142/161 patients (CR in 116, 72%; PR in 26, 16.1%) on 
mycophenolate, 53/54 (CR in 48, 88.9%; PR in 5, 9.3%) patients on azathioprine and 17/20 
(CR in 12, 60%; PR in 5, 25%) patients on methotrexate. Complete response was maintained 
throughout the follow up (with any dose of steroids) in 77 (47.8%), 25 (46.2%) and 8 (40%) 
patients on these drugs respectively. Though statistically not significant, sustained inactive 
disease was observed in numerically higher proportion of patients on MMF (59/161, 36.9%) 
followed by azathioprine (16/54, 29.6%) and methotrexate (5/20 (25%).  MMF was not 
associated with any serious adverse events, whereas cytopenia requiring hospitalisation was 
noted in 12 patients on azathioprine (0 vs 12, p 0.01). Tocilizumab was used in 44 patients 
during the total study period. Details of clinical profile and outcome of patients on biologics 
are not discussed here.  
  
p=0.71 
 Discussion:   
This is the largest single centre study describing long term outcome of a large cohort of 
patients with TA.  We studied 251 patients over a median follow up period of 42 (IQR: 24-
81) months using objective instruments like ITAS-A(CRP), TADS, other common 
biomarkers and angiography. We used steroid sparing immunosuppressants (predominantly 
Mycophenolate) from the beginning along with tapering schedule of steroid (predominantlly 
Deflazacort, an oxazoline derivative of prednisolone). In some cases with aggressive disease, 
we used TCZ for rapid control of disease activity and could achieve significant steroid 
sparing action. With this strategy, the majority (92.8%) of our patients had at least one period 
of stable disease (complete or partial response), and only 7.2% of our cohort had disease truly 
refractory to treatment till the last follow up (figure 2).  
At the very first follow up evaluation after initiation of our immunosuppression protocol, 215 
patients (86.7%) responded to treatment by our response criteria defined in the methodology, 
with complete response in176 (70.1%) and partial response in 42 patients (16.7%). Only 36 
patients (14.3%) were non-responders at that point of follow up. 
The initial complete response mentioned above was sustained throughout the entire follow up 
period in 65.9% of these responders in-spite of de-escalation of treatment as per our protocol 
(46.2% of the entire cohort). This was much higher than the figure of 17% reported in an 
earlier series from the Cleveland clinic foundation (CCF). In the CCF cohort, steroid sparing 
immunosuppressant was added only after patients relapsed on tapering of steroids [17] 
(figure-5). These 2 contrasting results emphasise the role of upfront use of steroid sparing 
immunosuppressant along with steroid from the very initial phase of treatment.  
  
 Figure-5: Comparison of outcome data of TA from literature 
Parameter Kerr etal, 
NIH 
(1994) 
Ishikawa 
etal 
(1994) 
CCF, USA 
(2007) 
Mayo 
Clinic, USA 
(2013) 
Japanese 
Ohigashi 
etal (2012) 
China 
(Yang L 
etal, 2014) 
Present 
study CMC 
Vellore 
(2017) 
Year 1970-90 1957-90 1992-2004 1984-2009 2000-2010 2002-2013 1998 - 2016 
Design Prospectiv
e 
Prospectiv
e 
Retrospectiv
e 
Retrospectiv
e 
Retrospectiv
e 
Retrospectiv
e 
Retrospectiv
e / 
prospective 
Follow up 
described 
(patients 
screened) 
45 (60) 120 (120) 30 (75) 79 (126) 35 (106) 326 (556) 251 (503) 
Follow up 
duration 
(years) 
5.5 15 3 5.5  
(IQR:2.9-
10) 
0.5- 5.0 5.0 ± 0.2  3.5  
(IQR: 2-6.8) 
 
Steroids 
used (%) 
80 80 93 92 79.2 85.9 95.2 
II line 
agent used 
(%)  
 
(MTX/AZ
A/ 
MMF/CSA 
in %) 
41.7 
 
 
Not 
specified 
- 73 
 
 
(43/7/7/0) 
66 
 
 
(58/ 19 
/18/0) 
18.9 
 
 
(50/0/0/ 35) 
4.1 
 
 
- 
93 
 
 
(9/19/62/0) 
Initial 
response to 
treatment 
(%) 
60 - 93 96 35 66.3 85.6 
Cumulative 
relapse rate 
at median 
follow up 
(%) 
80   96  46  70  - 27  
Long term 
sustained 
complete 
response 
(%)  
- - 17 - - - 46.2 
Death n, 
(%) 
2 (3) 13 (16) 3 (4) 6 (4.8) NR 32 (9.6) 2 (0.7) 
 
Only 22.3% of our patients with initial complete response had relapsed on de-escalation of 
therapy as per our protocol, which is less than half of that reported by Schmidt et al (46%) 
[9]. The cumulative relapse free survival (sustained remission) at 1, 3, 5 and 10 years in our 
study were 93%, 73%, 66% and 52% respectively. Escalation of treatment led to response 
 even in the relapsed patients. Nearly 80% of patients had CR or PR (2/3
rd
 had CR) at all the 
time intervals of follow up (figure 3B).  
In 34.6% of our patients, sustained inactive disease was observed throughout the follow up 
period with steroid dose of ≤ 5mg/day at the last follow up visit.  
Use of steroid sparing immunosuppressants in TA for maintenance of response has gained 
increased acceptance in recent times as compared to the past. Earlier reports from Mexico, 
Japan and India reported use of these agents only in minority of cases, in contrast to their use 
in >60% of TA patients in recently published series from France and USA [7, 9, 18- 21]. Our 
policy of concurrent initiation of immunosuppressants at the outset along with steroids in 
majority of our patients  (97.3%) may be the reason for better long term response in our 
cohort. This was in contrast to the modest results of CCF cohort, who were subjected to 
sequential approach with initial steroid alone therapy followed by the introduction of steroid 
sparing second line immunosuppressants only in those patients with relapsing disease [17].  
In addition, we followed a slow taper schedule of steroid therapy in our patients, as faster rate 
of reduction in steroid dose has been noted to be associated with relapsing disease [6]. Timely 
revascularisation procedures in our centre could have also contributed to good outcome by 
preventing ischaemic complications, as noted by Ishikawa et al [21].  Use of mycophenolate 
was much higher in our cohort as compared to other centres including CCF where 
methotrextae was the preferred 2
nd
 line agent.  We practise upfront institution of MMF, due 
to its higher safety data as well as its efficacy comparable to cytotoxics like 
cyclophosphamide in other autoimmune situations; our earlier study as well as the recent 
meta-analysis also reported efficacy of MMF in TA [22,23]. Therefore, it is likely that MMF 
along with steroids may have added to better outcome in our patients.  We did not come 
across any serious adverse event with the use of MMF, whereas cytopenia requiring 
hospitalisation was significant amongst our patients receiving azathioprine (n=12 out of 54, p 
0.01). 
Unlike other autoimmune diseases like lupus, inflammation in TA is thought to be more 
smoldering, though such presumptions could be due to lack of well-designed controlled trials 
and outcome studies.  Based on real life observations in our large clinic and a recent study by 
Yang et al using a relatively lower initial steroid dose in their Chinese cohort with TA [5], we 
have been switching over to initial steroid dose of 0.5 mg/kg/day (prednisolone or equivalent 
dose of deflazacort) in recent times from our earlier practice of using 1 mg/kg/day.  This gave 
 us an opportunity to compare the effects of the two doses and we found that patients on the 
0.5 mg/kg/day of initial steroid did just as good as the ones on 1mg/kg/day, in spite of the 
similar tapering schedule. This endorses the use of 0.5mg/kg/day as the initial dose of 
steroids in TA.  
Breakthrough biologicals (predominantly TCZ) in select cases with aggressive disease, in 
addition to upfront institution of tapering steroid plus steroid sparing immunosuppressive 
agents, may have also contributed further towards good outcome especially in our ‘difficult to 
control’ patients.  
Escalation of treatment as per our treatment protocol targeting an ITAS-A score of 0 during 
the follow up ultimately led to an overall response in 213 (84.9%) patients, with complete 
response in 176 (70.2%) and partial response in 37 (14.7%) at the last follow up visit. 
Although 35 (14.1%) of the entire cohort had active disease at last follow up, 20 of these 35 
patients did respond to immunosupression earlier in the course, thus exhibiting a  ‘relapsing 
and remitting course’ on de-escalation of immunosuppression as per our protocol. This kind 
of fluctuation of disease course while tapering immunosuppression is a common feature in 
most autoimmune rheumatic diseases. Figure 2 shows a total of 56 such patients at last visit. 
It is also reassuring that most of these patients with such grumbling course had also 
responded to aggressive breakthrough treatment as per our protocol.   
Medical treatment, predominantly comprising of deflazacort and mycophenolate in the vast 
majority of our patients with TA could also arrest or minimise damage progression in 68% of 
patients as assessed by TADS score. The increment in damage was directly associated with 
persistent disease activity, thereby emphasizing the importance of strict and sustained control 
of disease activity in TA. There were only 2 fatalities (1.3%) in our total cohort, figures much 
lower than that published in literature.  
Heterogeneity in definition of outcome measures renders comparison between various large 
series of TA difficult. Sustained inactive disease and sustained CR were objectivised as 
primary outcomes in our study, somewhat similar to the long term outcome measures 
addressed in the series by Cleveland clinic foundation. Such stringent outcome measure is 
desirable in a disease like TA, as clinically stable disease may have subclinical histological 
inflammation with disease progression in 20% to 40% of such patients [17].  
 Use of more recent objective tools to define disease extent, activity and damage progression 
are the strengths of this study. We have used ITAS-2010, a tool validated amongst Indian 
patients, along with laboratory and angiographic details to assess disease activity in contrast 
to studies from USA, France and China who used NIH criteria [3,5,7,9,16,17-21]. The major 
limitation of our study is the retrospective component of our study.  
Overall, it was pleasing to note that only 15 of 251 patients were truly refractory to treatment 
till the last follow up; the vast majority had favourable long term outcome and were 
responsive to our medical treatment protocol with immunosuppression with or without 
biologics therapy.  
Further, we could define the predictors of sustained inactive disease which may act as a 
useful model for future studies. Our attempt to develop such a prediction model identified 
low baseline ESR, CRP, low DEI.Tak scores and type 4 TA as predictors of sustained 
inactive disease with a sensitivity of 70% and a specificity of 61.1%. On the other hand, 
isolated abdominal aorta involvement and lower age of onset were found to be negative 
predictors of persistently refractory disease.  
Randomised controlled trial or observational prospective cohort study with the aim to 
determine long term outcome using uniform treatment protocol is a need of the hour. 
Conclusions: Combination of tapering steroids and steroid sparing immunosuppressants like 
MMF from the beginning was our primary medical regimen in TA. Biologics like TCZ was 
used only in select situations as a breakthrough option for rapid control of disease activity. 
Our strategy could stabilise disease activity in 92.8% of our patients at various time points of 
follow up; only 7.2% of our cohort were truly refractory to treatment. We could achieve 93%, 
73%, 66% and 52% relapse free survivals at 1 year, 3 year, 5 year and 10 year respectively. 
Damage progression was also arrested in 68% of our patients and only 2 fatalities were 
observed in this cohort. Initial steroid dose of 0.5mg/kg/day with slow taper had similar 
response and relapse rate as 1mg/kg/day dose. MMF was the cornerstone steroid sparing 
immunosuppressant and the major maintenance agent to prevent relapses with better safety 
profile. 
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